Drug Stockpiling: Pharma Companies Secure MFN Deals
- WASHINGTON - Brand drugmakers have agreed to donate bulk ingredients to a national stockpile as part of deals with the Trump administration focused on lowering U.S.
- The administration announced Friday that nine more drugmakers agreed to so-called most favored nation prices, bringing the total number of companies to sign such deals this year to...
- Some of the nine companies agreed to donate six months' worth of certain drug ingredients to the Strategic Active Pharmaceutical Ingredient reserve and to make finished-dose products from...
“`html
Trump Administration Secures Drug Price agreements and Boosts National Stockpile
What Happened: Drug Price Agreements and Stockpile Donations
WASHINGTON – Brand drugmakers have agreed to donate bulk ingredients to a national stockpile as part of deals with the Trump administration focused on lowering U.S. drug prices to levels available to other wealthy countries.
The administration announced Friday that nine more drugmakers agreed to so-called most favored nation prices, bringing the total number of companies to sign such deals this year to 14. The agreements are similar to those shared earlier this year: brand drugmakers will lower prices and boost domestic manufacturing in return for avoiding tariffs.
But the stockpile is a new aspect. Some of the nine companies agreed to donate six months’ worth of certain drug ingredients to the Strategic Active Pharmaceutical Ingredient reserve and to make finished-dose products from those ingredients during emergencies.Among them, Merck will supply the bulk ingredients for its antibiotic ertapenem; Bristol Myers Squibb will provide the blood thinner apixaban, commonly sold under the brand name Eliquis; and GSK will donate albuterol.
Why This Matters: The Context of U.S.Drug Pricing
The United States has consistently faced considerably higher drug prices compared to other developed nations.this disparity is frequently enough attributed to a complex interplay of factors, including limited government negotiation power, patent protections, and the role of pharmacy benefit managers (PBMs). The Trump administration’s “most favored nation” approach aims to address this by tying U.S. drug prices to the lowest prices available in other countries.
The Strategic Active pharmaceutical Ingredient Reserve (SAPIR) is a critical component of national preparedness. Maintaining a domestic stockpile of essential drug ingredients reduces reliance on foreign suppliers, particularly during public health emergencies like pandemics or natural disasters. This initiative aims to strengthen the U.S. supply chain and ensure access to vital medications.